2023
Peripheral Blasts in a Patient Receiving Chemotherapy
Kshattry S, Parker T, Huntington S. Peripheral Blasts in a Patient Receiving Chemotherapy. JAMA 2023, 330: 1581-1582. PMID: 37801303, DOI: 10.1001/jama.2023.17117.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinGemcitabineGranulocyte Colony-Stimulating FactorHumansLeukopoiesisUrinary Bladder NeoplasmsAssessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leukemia & Lymphoma 2023, 64: 1752-1770. PMID: 37497877, DOI: 10.1080/10428194.2023.2234525.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsHealth Care CostsHumansLymphoma, Mantle-CellMedicarePatient Acceptance of Health CareRetrospective StudiesRituximabUnited StatesConceptsHealthcare resource utilizationMantle cell lymphomaElderly patientsTreatment patternsCell lymphomaUnmet needLater linesNational Medicare claimsHalf of patientsHealth care utilizationElderly Medicare beneficiariesLarge unmet needReal-world outcomesCause hospitalizationOverall survivalCare utilizationHospitalization ratesNovel therapiesMedicare claimsL regimenHealthcare costsMedicare beneficiariesL treatmentPatientsLymphomaDTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
Huntington S, Schuster S, Ding W, Koehler A, Brander D, Rosenthal A, Leis J, Tun H, Moustafa M, Iqbal M, He W, Kearney A, McKinlay T, Gui M, Mato A. DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal Of Hematology 2023, 98: 739-749. PMID: 36810799, DOI: 10.1002/ajh.26888.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsEverolimusHumansLeukemia, Lymphocytic, Chronic, B-CellLymphomaMiddle AgedNeoplasm Recurrence, LocalProtein Kinase InhibitorsSirolimusTOR Serine-Threonine KinasesTreatment OutcomeConceptsBruton tyrosine kinase inhibitorsTyrosine kinase inhibitorsRefractory lymphomaTriplet combinationsKinase inhibitorsOral combination therapyPhase 2 doseOpen-label studyDose-escalation studyAccelerated titration designB-cell NHLNovel Bruton's tyrosine kinase inhibitorEligible patientsEverolimus 5Refractory CLLEscalation studyTriplet therapyMedian ageCombination therapyHodgkin's lymphomaIMiD therapyImmunomodulatory agentsClinical activityDoublet combinationsPreclinical studiesTreatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsHumansLymphoma, Mantle-CellNeoplasm Recurrence, LocalRituximabTreatment Outcome
2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood 2021, 138: 1768-1773. PMID: 34297826, PMCID: PMC8313815, DOI: 10.1182/blood.2021011841.Peer-Reviewed Original ResearchCost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBortezomibCost-Benefit AnalysisDexamethasoneHumansHydrazinesMultiple MyelomaNeoplasm Recurrence, LocalQuality-Adjusted Life YearsTriazolesConceptsIncremental cost-effectiveness ratioRefractory multiple myelomaMultiple myelomaWeekly selinexorR Multiple MyelomaProgression-free survivalUS payer perspectiveCost-effectiveness ratioWeekly bortezomibTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessBortezomibIncremental costMyelomaDexamethasoneSelinexorQALYVDPatientsCost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesCost-Benefit AnalysisDexamethasoneDrug CostsHealth Care CostsHumansLenalidomideMarkov ChainsMultiple MyelomaOutcome Assessment, Health CareProgression-Free SurvivalQuality-Adjusted Life YearsConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyelomaEvaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
Patel KK, Stein S, Lacy J, O’Hara M, Huntington SF. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA Network Open 2021, 4: e2033441. PMID: 33433598, PMCID: PMC7804917, DOI: 10.1001/jamanetworkopen.2020.33441.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCetuximabColorectal NeoplasmsCost-Benefit AnalysisFemaleFluorouracilHumansIrinotecanLeucovorinMaleMarkov ChainsMiddle AgedNeoplasm MetastasisProto-Oncogene Proteins B-rafQuality-Adjusted Life YearsSulfonamidesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioDoublet therapyStandard chemotherapyColorectal cancerCost-effectiveness modelProbabilistic sensitivity analysesParametric survival modelingBEACON trialEconomic evaluationMAIN OUTCOMECurrent pricingLife yearsIncremental costLifetime costsBest supportive careLines of therapyProlonged overall survivalLarge clinical trialsClinical trial designHigh microsatellite instabilityCumulative costsOverall survivalSupportive care
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsHumansImmunotherapyLenalidomideLymphoma, Large B-Cell, DiffuseMiddle AgedRituximabConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profileCost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisHumansImmunoconjugatesLymphoma, Large B-Cell, DiffuseQuality-Adjusted Life YearsConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCLEfficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBayes TheoremHumansLenalidomideMultiple MyelomaTreatment OutcomeConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probability
2018
Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCost of IllnessFemaleHealth Care CostsHospitalizationHumansInsurance Claim ReviewLymphoma, Large B-Cell, DiffuseMaleMedicareNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeUnited StatesConceptsDiffuse large B-cell lymphomaHealth care costsLarge B-cell lymphomaFirst-line treatmentB-cell lymphomaCare costsHealth care expendituresCare expendituresHigher health care costsOffice visit costsSecond-line therapyFirst-line therapyHigher medical costsLikelihood of relapseRelapsed cohortMedicare patientsMedicare claimsMedical costsVisit costsPropensity scoreOlder adultsPatientsLymphomaTherapyTreatmentReal-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era
Mato A, Jahnke J, Li P, Mehra M, Ladage VP, Mahler M, Huntington S, Doshi JA. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica 2018, 103: e462-e465. PMID: 29700170, PMCID: PMC6165790, DOI: 10.3324/haematol.2017.185868.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChlorambucilDisease-Free SurvivalFemaleHumansInsurance Claim ReviewLeukemia, Lymphocytic, Chronic, B-CellMaleMedicareRetrospective StudiesRituximabSurvival RateUnited States
2017
R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan‐Dabaja M, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis. British Journal Of Haematology 2017, 180: 534-544. PMID: 29265182, DOI: 10.1111/bjh.15051.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDisease ManagementDoxorubicinEtoposideFemaleHumansLymphoma, B-CellMaleMediastinal NeoplasmsMiddle AgedNeoplasm GradingNeoplasm StagingPrednisoneRecurrenceRetrospective StudiesRituximabTreatment FailureTreatment OutcomeVincristineYoung AdultConceptsPrimary mediastinal large B-cell lymphomaDA-R-EPOCHDose-adjusted R-EPOCHNon-Hodgkin lymphomaB-cell lymphomaR-CHOPR-EPOCHMediastinal large B-cell lymphomaPrimary mediastinal B-cell lymphomaLarge B-cell lymphomaR-CHOP patientsComplete response rateMediastinal B-cell lymphomaTreatment-related complicationsPhase II trialProgression-free survivalR-CHOP chemotherapyTreatment-related toxicityUnique clinicopathological featuresMulti-center analysisII trialOverall survivalSecondary outcomesPrimary outcomeClinicopathological featuresLong-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDecitabineDNA MethylationFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesPrognosisRetrospective StudiesStem Cell TransplantationSurvival RateSurvivors
2015
Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56: 2579-2584. PMID: 25629993, DOI: 10.3109/10428194.2015.1007506.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFluorodeoxyglucose F18HumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOutcome Assessment, Health CarePositron-Emission TomographyPrednisoneProportional Hazards ModelsRemission InductionRetrospective StudiesRituximabTomography, X-Ray ComputedVincristineYoung AdultConceptsDiffuse large B-cell lymphomaFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyLarge B-cell lymphomaFirst-line therapyMajority of patientsTomography-computed tomographyB-cell lymphomaI-PETPET/CTFrontline therapyClinical utilityInterim PET/CTTreatment PET/CTProgression-free survivalEnd of treatmentLittle clinical utilityPost-treatment assessmentRetrospective studyPretreatment stagingMultivariable modelingPatientsTreatment imagingTherapy
2012
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy
Huntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsComorbidityCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleGeriatricsHumansLymphoma, Large B-Cell, DiffuseMaleMedical OncologyMiddle AgedPrednisoneRemission InductionRetrospective StudiesRituximabTreatment OutcomeVincristineConceptsNon-Hodgkin lymphomaLarge cell lymphomaCell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaChemotherapy dose reductionsTreatment-related toxicityR-CHOP treatmentSingle-institution studyB-cell lymphomaCurative intentRelative chemotherapyComplete remissionPrimary therapyElderly patientsSupportive careTreatment toxicityAged patientsPatient populationTreatment outcomesRetrospective analysisDose reductionElderly populationPatientsLymphoma